A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains

See allHide authors and affiliations

Science Translational Medicine  09 Jun 2021:
Vol. 13, Issue 597, eabf6348
DOI: 10.1126/scitranslmed.abf6348

One Shot for Lassa Virus

Up to 180 million people are at risk for infection with Lassa virus (LASV), and the endemic region for LASV is expanding. Thus, there is a critical need to develop a vaccine against LASV, preferably one that protects against multiple lineages of LASV, generates durable immune responses, and can be administered in a single dose. To that end, Mateo et al. investigated the ability of a recombinant measles virus vaccine expressing LASV proteins (MeV-NP) to protect nonhuman primates against multiple strains of LASV and to provide protection over a year after vaccination, showing that the vaccine was effective at both. MeV-NP, which is now in clinical trials, represents an advance in the field of LASV vaccine development.

View Full Text

Stay Connected to Science Translational Medicine